JSMO/ESMO Joint Symposium
Optimal treatment for metastatic colorectal cancer
(based on revised, latest ESMO, JSCCR treatment guideline)
The ESMO Colorectal Cancer Consensus Guidelines for the treatment of unresectable colorectal cancer were revised in 2016, and work on revising the Japanese guidelines for the treatment of colorectal cancer is well underway. The former primarily set therapeutic goals, while the feature of the latter is that it lists evidence-based regimens. The ESMO/JSMO Joint Symposium will discuss the optimization of treatment according to these guidelines.
JSMO/MOGA, KACO, CSCO, SSO Joint Symposium
Precision medicine, its current status and possibilities for future collaborations
JSMO/ASCO Joint Symposium
Current status of molecular targeted therapy in lung cancer
JSMO/ASCO Special Lecture
Training Clinical Investigators for Medical Oncology Trials
JSMO/ESMO Special Lecture
Evolving treatment for metastatic colorectal cancer
Cancer Data Collaboratives: A Requirement for Personalized Medicine
Molecular profiling of Bile duct cancer
Molecular Genetics of Endometrial Carcinoma
Nation-wide basket/umbrella type study for precision medicine
With a rapid progress of NGS panel developments, genome-baed precision medicine is being implecated into daily practice throughput the world. However, clinical evidence is still limited particularly in patients with rare driver gene alterlations. It is an urgent need to integrate clinical outcomes of world-wide IND registration tirals. In this session, three major basket/umbrella trials with nation-wide genome screenig are discussed with respect to current status and future international collaborations.
Comprehensive Symptom Screening and Early Palliative care
—From the Start of Cancer Treatment—
It has been suggested that early palliative care may affect not only quality of life but also cancer treatment, and the importance of engaging in palliative care from soon after cancer diagnosis is now being recognized. With respect to palliative care at designated cancer care hospitals, screening for symptoms from the time of diagnosis and appropriate intervention are among the stated conditions for designation as a cancer care hospital. However, early screening depends on the situations in these cancer care hospitals as well as local circumstances, and there is huge variation in how this is actually dealt with, including various problems with systems and staffing. In this session, we will hear about early palliative care in Canada, which is a pioneer in this area, followed by a description of initiatives in three hospitals that are actively engaged in palliative care screening using a range of different methods, with the aim of obtaining hints on symptomatic screening for palliative care in future.
Latest status of EGFR-TKIs in EGFR mutant NSCLCs
Therapeutic strategy for Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lung cancer (NSCLC) has dramatically changed along with the development of various EGFR tyrosine kinase inhibitors (TKIs). 1st/2nd generation EGFR TKIs are indispensable agents in EGFR mutant NSCLCs treatment strategy. Lately, 3rd generation EGFR TKI osimertinib was approved in Japan and other countries for the treatment of T790M positive NSCLC which acquired resistance to 1st/2nd generation EGFR TKIs. However, many problems remain unresolved; overcoming acquired resistance, proper way of using EGFR TKIs differently, tumor heterogeneity etc. We will discuss these issues in this session.
Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer
Immune checkpoint inhibitors have been greatly transforming the system of treatment for lung cancer in recent years. Many questions remain unresolved, however, including biomarkers, when to use which drug, the significance of immune checkpoint inhibitors for lung cancer with driver oncogenes, and the potential for combination therapies. This session will introduce the latest discoveries about immune checkpoint inhibitors, and deepen the discussion of how to overcome these issues.
Biomarker research and treatment strategy for metastatic colorectal cancer
Recent rapid advances in research on biomarkers in colorectal cancer mean that screening for oncogene mutations in the EGFR pathway may potentially offer indications for the use of immune checkpoint inhibitors or their inclusion in combination therapies. In this session, top leaders from Japan and overseas will discuss treatment strategies based on the latest data.
How can we manage the international gap in development of chemotherapy for gastric cancer?
Chemotherapy for advanced pancreatic cancer in a new era
Pancreatic cancer is still one of most dismal disease, and chemotherapy plays an important role to improve the prognosis. Since FOLFIRINOX and combination nab-paclitaxel with gemcitabine have recently been introduced to chemotherapy for advanced pancreatic cancer addition to gemcitabine, erlotinib and S-1, treatment strategy has been changed not only in metastatic disease but also in locally advanced disease and adjuvant setting. In this symposium, current status and future perspective of chemotherapy for pancreatic cancer is discussed from various points of view.
Present and future status of hereditary cancer prophylactics
Circumstances surrounding hereditary cancer has been greatly changed together with increasing understanding of hereditary breast and ovary cancer (HBOC) in public, recent publication of revised "Guidelines for the clinical practice of hereditary colorectal cancer", and recent attempt to build a medical treatment system of hereditary cancers by the government. On that occasion how to face to the hereditary cancer is one of the important issue in the field of clinical oncology. In this symposium, we will invite domestic and international authorities and will discuss current status and future direction of the treatment and the chemoprevention (based on several international clinical trials) on HBOC, familial adenomatous polyposis (FAP) and Lynch syndrome related cancers.
Immunotherapy for head and neck cancer: Future direction
Nivolumab significantly improved overall survival for patients with, recurrent or metastatic SCCHN after platinum therapy compared to single-agent systemic therapy of investigator’s choice in a phase 3 trial (CheckMate 141). A number of clinical trials of immune checkpoint inhibitor for head and neck cancer are now ongoing not only for recurrent or metastatic but also locally advanced SCCHN, indicating that immune checkpoint inhibitor could change the treatment strategy for head and neck cancer. In this session, future directions of immune checkpoint inhibitor will be discussed.
New therapeutic strategy for endocrine-refractory metastatic breast cancer
Overcoming endocrine-resistance is most important task in estrogen receptor positive metastatic breast cancer. There is clear evidence that PI3K/Akt/mTOR and CDK4/6 play important roles in endocrine-resistance, and their inhibitors recently demonstrated significant benefit. However, predictive biomarker, treatment line and sequence of them are still unresolved issue. Moreover, it has been revealed that alterations of estrogen signaling such as ESR1 mutation are one of the key mechanism of endocrine-resistance. In this session, we will review and discuss these issues.
Treatment Strategy for Castration Resistant Prostate Cancer, 2017
Enzalutamide, Abiraterone and cabazitaxel were approved for treatment of Castration Resistant Prostate Cancer (CRPC) in Japan, 2014. The information of each drugs characterization is confuzed, the strategy for CRPC is still controversial. Furthermore, survival benefit of combination therapy of androgen deprivation therapy and Docetaxel was reported in CHARRTED clinical trial. In this session, we will review and discuss current strategy for CRPC.
Recent advances in the treatment of multiple myeloma
It is an exciting time for the myeloma patients with more effective therapeutic options. Promising new drugs like pomalidomide (immunomodulatory drugs; IMiDs), carfilzomib (protessome inhibitors; PIs) and panobinostat (histone deacetylase (HDAC) inhibitors) are now available. Recent trials have suggested that combination of these new agents with each other, or with alkylating agents resulted in deeper responses and significantly improved outcomes. Maintenance therapy or prolonged treatment also improves the duration of clinical responses. In addition, there is a growing interest in the use of immunomodulatory techniques, including monoclonal antibodies such as Daratumumab (anti-CD38) and elotuzumab (anti-CS1), vaccine therapy, checkpoint inhibitors, autologous T cells, and engineered T cells. In this session, we will review the efficacy and toxicity of emerging treatment options available to patients with multiple myeloma.
Treatment of carcinoma of unknown primary: Evidence-based or Science-based?
Cancer Immunotherapy -What's the next?
The immune checkpoint therapy shed new light on cancer immunotherapy. Other topics such as chimeric antigen receptor (CAR) T-cell therapy and the targeted therapy of suppressor cells such as regulatory T cells also pay attention. In this session, we will discuss the future immunotherapies by reviewing the detailed mechanisms of cancer immunity.
Improving the evidence base for treating elderly patients with cancer
In clinical research for elderly people, there are many problems to be solved such as definition of object (eg, eligibility criteria and exclusion criteria), design of research. Also, in order to generalize the standard treatment established by non-elderly people, attention on practice is also necessary. The International Gerontological Society Society recommends assessment such as functional assessment of elderly people, but devises are necessary for utilization in practice. Discuss current issues and future prospects from researchers leading domestic and international clinical research.
Oral supportive care in cancer- promoting evidence-based clinical practices
Oral problems are common in cancer patients. They can be a part of the disease itself; they can develop as a result of treatment; they can accompany other symptoms and present as a comorbidity; and they can even first present after the original disease itself has been cured. Oral symptoms can be complex to treat, both preventing administration of potentially life-saving treatment, and also directly causing additional life-threatening complications. However, many symptoms can be treated, and lead to tremendous relief of suffering for the patient. This symposium focus on this unique set of symptoms, and provides an international, multi-professional reference with up to date, evidence-based, clinically relevant advice. It covers topics such as more common oral complications of cancer and its treatment.
This symposium is for the wide multi-disciplinary team involved in treating the cancer patient with oral problems; this includes oncologists (both medical and clinical), oncology nurses, oral medicine specialists, palliative care physicians and nurses, special care dentists, special care dental nurses/hygienists, and therapy radiographers.
Whole Person Care —Care for cancer patients—
We will hear a general explanation of the concept of “whole person care” recently proposed by McGill University, the birthplace of palliative care. The aim of this proposal is to integrate both “cure” and “healing” and to extend an understanding of their relationship not only to patients but to all healthcare professionals, including medical students. In this session Dr. Tom Hutchinson, the central figure in whole person care at McGill University today, will give us an outline of whole person care, and two other speakers will discuss how this can be applied in practice in the Japanese situation and how it can be used in actual cancer treatment.
Newest knowledge in gastric cancer
Although the molecular targeted agents of trastuzumab and ramucirumab have already come into use as standard chemotherapy for gastric cancer, many other novel agents have proved unsuccessful during development. Immune checkpoint inhibitors are now the focus of attention, as they have been found to be effective against gastric cancer. In this session, we will discuss the status of new drug development and future directions on the basis of clinical and biological characteristics.
Guidelines of Molecular Targeted Therapies for Thyroid Cancer
Angiogenesis inhibitors, which are molecular targeted drugs, have now been approved for the treatment of thyroid cancer and are coming into everyday clinical use. However, in many cases tumors grow relatively slowly even after becoming resistant to radioactive iodine therapy, and cause few metastasis-associated symptoms. The side effects of angiogenesis inhibitors are anything but mild, and decisions on whether to use these drugs and when to start such treatment are frequently problematic. Treatment guidelines provide one factor that may be of use during decision-making in clinical settings. In this session, we will discuss the use of angiogenesis inhibitors and when to start such treatment in light of the presentation of the various sets of guidelines.
Can preoperative therapy guide decisions on adjuvant systemic therapy?
Pre-operative therapy makes it possible to select most appropriate therapy watching response of treatment. In CREAT-X study, post-operative capecitabine improved survival of patients with residual disease after pre-operative chemotherapy. Furthermore, NEOS study is ongoing in Japan, which is looking at meaning of adjuvant chemotherapy according to response to pre-operative endocrine therapy. In this session, we will widely review and discuss utility of response guided therapy based on pre-operative therapy.
Multidisciplinary approach to soft tissue sarcoma: Current management
Although evidence for the effectiveness of chemotherapy for localized soft-tissue sarcoma has yet to be established, chemotherapy is now recommended for tumors that are highly malignant, originate in deep tissues, or are very large in size. Evidence for the use of chemotherapy to treat recurrent or advanced soft-tissue sarcoma has been reported. In the past two years, a number of new molecular targeted drugs have been approved for the treatment of soft-tissue sarcoma, but a treatment strategy has yet to be established, including one for conventional chemotherapy. In this symposium, we will discuss what sort of treatment strategies clinicians are considering for soft-tissue sarcoma.
The future of immune checkpoint therapy
Immune checkpoint therapies represent highly clinical effect on various types of cancers such as malignant melanoma, non-small cell lung cancer and renal cell cancer. The biomarkers that predict the clinical efficacy have not been fully understood and under intense evaluation. In this session, we will discuss the next generation immune checkpoint therapies with evaluating the current immune therapies.
Current landscape and future perspectives of biomarker study in breast cancer
It has been clarified that breast cancer is not one disease, but heterogeneous tumor by recent gene expression profiling and genome sequencing. To provide optimal treatment by these genomic information, so called "precision medicine" is needed. In addition, it is very important to consider immune effect in host side for breast cancer therapy. In this session, we discuss currently available biomarkers or promising future biomarkers.
Current concepts and future perspective of chemotherapy for soft tissue sarcoma
Soft tissue sarcoma is uncommon, and is one of the best-known rare cancers. Several new drugs have been developed over the past three years, and these are now undergoing clinical trials. Treatment strategies for soft tissue sarcoma are thus changing, as although formerly few effective drug treatments were available, the scope of treatment options is now increasing. In this session, we will hear about the development of novel agents, clinical trials, and current treatment strategies for soft tissue sarcoma, from presenters with wide-ranging experience in the treatment of soft tissue sarcoma and extensive involvement in new drug development and clinical studies.